KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial.

Naruto Taira, Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Satoshi Morita, Norikazu Masuda

Breast 88 104790

PMID42061030
PMCIDPMC13141780
DOI10.1016/j.breast.2026.104790
发表日期2026-04-30
摘要

摘要

BACKGROUND: Retreatment with pertuzumab has demonstrated survival benefit in previously treated human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer, but its effect on health-related quality of life (HRQoL) is not well established. METHODS: This secondary analysis of the randomized, open-label phase III PRECIOUS trial evaluated HRQoL in women previously treated with pertuzumab, trastuzumab, and chemotherapy. Patients were randomized 1:1 to pertuzumab plus trastuzumab plus chemotherapy (PTC) or trastuzumab plus chemotherapy (TC). HRQoL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). The primary endpoint was time-to-deterioration (TTD) in the Breast-Trial Outcome Index (B-TOI), defined as a ≥5-point decline. Secondary endpoints included TTD in the FACT-B total score, General Subscale, and Breast Cancer Subscale. Longitudinal changes were analyzed using linear mixed-effects models. RESULTS: Of 217 eligible patients, 178 were included in the HRQoL analysis (median age: 57 years in PTC and 60 years in TC). No significant between-group differences in TTD for B-TOI were observed (hazard ratio, 1.22; 95% CI, 0.86-1.90; p = 0.23). Secondary TTD endpoints also showed no differences. Mixed-effects models indicated that TC had better B-TOI and Breast Cancer Subscale scores at week 6, but these early differences were not sustained beyond week 12. CONCLUSION: Pertuzumab retreatment was not associated with clinically meaningful deterioration in HRQoL. These findings support the use of dual HER2 blockade beyond progression in appropriately selected patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。